NexGard™ (afoxolaner) Chewables

In studies, NexGard killed >99% of existing fleas within 12 hours of treatment and 100% of existing American dog ticks within 48 hours of treatment.

### Fleas
- Kills fleas fast—before they can lay eggs.
  - Began killing fleas within 4 hours
  - Killed 99.5% of existing fleas in 8 hours
  - Killed >81% of fleas within 12 hours of treatment or reinfection for an entire month.
- Prevents flea infestations

### Ticks
- Kills ticks. In studies, efficacy against ticks was measured 48 hours after treatment:
  - Killed 98.4% of existing Black-legged (deer) ticks (*Ixodes scapularis*).
  - Killed 100% of existing Lone-star ticks (*Amblyomma americanum*).
  - Killed 100% of existing American dog ticks (*Dermacentor variabilis*).

The first and only prescription-only, soft, beef-flavored chew for dogs that kills fleas AND ticks

- No need to administer with food
- FDA approved for puppies 8 weeks or older weighing >4 pounds
- Lasts a full month
- Sold directly to veterinarians
- A vegetable-based, beef-flavored, meatless chew that may be suitable for dogs with beef allergies
- Not just lab-tested, real-world tested

### IMPORTANT SAFETY INFORMATION
For use in dogs only. The most common adverse reaction is vomiting. Other adverse reactions are dry/flaky skin, diarrhea, lethargy, and anorexia. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures.


* Efficacy against Lone-star ticks was evaluated 48 hours after treatment (day 2) and 72 hours after infestation thereafter.
Afoxolaner: Safe and strong all month long.

Afoxolaner is a molecule developed specifically for the treatment of fleas and ticks that prey on dogs. Afoxolaner binds to flea and tick nerve cell chloride channels activated by the neurotransmitter GABA (gamma-aminobutyric acid), which causes uncontrolled hyperexcitation of the central nervous system and death in fleas and ticks. Afoxolaner acts selectively on the nervous systems of fleas and ticks because the GABA-gated chloride channels of these pests are much more sensitive to afoxolaner than those of mammals.

Afoxolaner in action

Afoxolaner selectively binds to a distinct site within chloride channels of the nervous system of fleas and ticks. This leads to prolonged firing of neurons, nervous system hyperexcitation, uncontrolled activity of the central nervous system, and death of the fleas or ticks.

Afoxolaner in the dog

After oral administration of NexGard to dogs, afoxolaner:

• Is rapidly absorbed into the bloodstream, reaching peak plasma levels in 2 to 4 hours
• Binds predominantly to plasma proteins while unbound afoxolaner is distributed throughout tissues
• Is slowly eliminated from the body through metabolism and biliary excretion
• Has a terminal half-life of approximately 15 days

Afoxolaner sustains excellent ectoparasitic activity for a FULL month

• The minimum monthly oral dose of 2.5 mg/kg maintains blood levels that are above the effective concentration that kills 90% of fleas in 24 hours and American dog ticks in 48 hours (EC$_{90}$).*

The FDA has approved NexGard for use in puppies 8 weeks of age or older weighing more than 4 pounds.
NexGard was proven safe and effective in a field study that featured client-owned dogs in their natural flea-infested environments during a 3-month period.5

NexGard Insert

### EFFICACY

<table>
<thead>
<tr>
<th>Description</th>
<th>Treatment Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dogs from 186 households were treated with NexGard</td>
<td></td>
</tr>
<tr>
<td>Households had varying levels of flea infestation</td>
<td></td>
</tr>
<tr>
<td>Many homes had multiple pets</td>
<td></td>
</tr>
</tbody>
</table>

### SAFETY

<table>
<thead>
<tr>
<th>Description</th>
<th>Treatment Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dogs were brought in for a flea count on their first visit; then given NexGard. They returned to their homes where they were continually exposed to fleas. Dogs then returned to their veterinarians for 2 more doses over the next 2 months.</td>
<td></td>
</tr>
<tr>
<td>Visit 0: Average pretreatment flea count was 26.5</td>
<td></td>
</tr>
<tr>
<td>Visit 1: 98.0% flea reduction 30 days after first NexGard</td>
<td></td>
</tr>
<tr>
<td>Visit 2: 99.7% flea reduction 30 days after second NexGard</td>
<td></td>
</tr>
<tr>
<td>Visit 3: 99.9% flea reduction 30 days after third NexGard</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Afoxolaner</th>
<th>Oral Active Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting (with and without blood)</td>
<td>4.1%</td>
<td>12.5%</td>
</tr>
<tr>
<td>Dry/Flaky Skin</td>
<td>3.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Diarrhea (with and without blood)</td>
<td>3.1%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>1.7%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1.2%</td>
<td>4.5%</td>
</tr>
</tbody>
</table>

**IMPORTANT SAFETY INFORMATION:** For use in dogs only. The most common adverse reaction is vomiting. Other adverse reactions are dry/flaky skin, diarrhea, lethargy, and anorexia. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures.
Satisfaction is our goal...

For your patients, clients, and you

<table>
<thead>
<tr>
<th>DOGS</th>
<th>CLIENTS</th>
<th>VETERINARIANS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Easy to take</td>
<td>Easy to give</td>
<td>Sold directly to veterinarians/available by prescription</td>
</tr>
<tr>
<td>Highly palatable&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Client Connection&lt;sup&gt;TM&lt;/sup&gt; program sends educational material and high-value coupons to clients</td>
<td>Antidiversion technology monitored by Pinkerton Consulting &amp; Investigations to help keep NexGard in the veterinary channel</td>
</tr>
<tr>
<td>Dogs prefer NexGard over Comfortis&lt;sup&gt;7&lt;/sup&gt; (spinosad) 19 to 1</td>
<td>CLIENT CONNECTION program drives pet owners to your practice with coupons/information that appear to come from your practice</td>
<td>Available in 4 sizes for easy stocking and dispensing • Small dog: 4.0 to 10.0 lb • Medium dog: 10.1 to 24.0 lb • Large dog: 24.1 to 60.0 lb • Extra large dog: 60.1 to 121.0 lb • &gt;121 lb: Administer appropriate combination of chews</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consumer promotion through TV, print, and online</td>
</tr>
</tbody>
</table>

<sup>6</sup> Data on file at Merial.  
<sup>7</sup> Data on file at Merial.

---

**NexGard is available in 4 sizes (both 3 packs and 6 packs):**

**IMPORTANT SAFETY INFORMATION:**  
For use in dogs only. The most common adverse reaction is vomiting. Other adverse reactions are dry/flaky skin, diarrhea, lethargy, and anorexia. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures.

---

See page 95 for Full Prescribing Information.  
**NexGard** and Client Connection are trademarks of Merial.  
©2014 Merial Limited, Duluth, GA. All rights reserved.  
NEX14PBCLINBRIEFINSRT-R (07/14)

---

<sup>TM</sup>NexGard and Client Connection are trademarks of Merial.